PATHOCIL (dicloxacillin sodium) by Thayer Medical is clinical pharmacology microbiology mechanism of action penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. Approved for the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. First approved in 1968.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
PATHOCIL (dicloxacillin sodium) is a penicillinase-resistant penicillin oral antibiotic approved in 1968 for treating infections caused by penicillinase-producing staphylococci. It works by inhibiting bacterial cell wall biosynthesis, exerting bactericidal action during active microbial multiplication. The drug is rapidly absorbed orally with peak serum levels in 1–1.5 hours and is primarily excreted unchanged in urine with a short half-life of approximately 0.7 hours.
As an approaching LOE product with minimal linked job openings, the brand team is likely in sustained-yield or runout mode with reduced headcount and investment focus.
CLINICAL PHARMACOLOGY Microbiology Mechanism of Action Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. Antibacterial Activity…
Worked on PATHOCIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on PATHOCIL in a LOE-approaching environment offers limited career advancement; roles are typically focused on managing decline, maintaining compliance, and optimizing reimbursement in a commoditized market. This is not a growth opportunity and may involve organizational right-sizing.